The BET inhibitors (BETis) JQ1 [31] and I-BET [32], which block BRD4 binding to acetylated histones and specifically downregulate key downstream oncogenes, have been used to treat BRD4-associated cancers [4,25,28]. This evidence concerns the gene BRD4 and cancer.